Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.
Zepbound, Lilly and Mounjaro
24/7 Wall St. on MSN20h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
GlobalData on MSN22h
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400mEli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Zepbound and Lilly's other blockbuster diabetes drug, Mounjaro, belong to a class of drugs called GLP-1 agonists. Analysts have forecast the market for GLP-1 drugs could reach at least $150 ...
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...
Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback